Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

Share Price is delayed by 15 minutes
Get Live Data
4,664.00    -214.00 (-4.39%)
Bid:
4,682.00
Ask:
4,686.00
Spread: 4.00 (0.085%)
Market Cap: £17.62b
HLMA Live PriceLast checked at - London Stock Exchange

Intraday Halma Share Chart

Trading Update

13 Mar 2025 07:00

RNS Number : 4586A
Halma PLC
13 March 2025
 

Halma plc

Trading update

 

Halma, the global group of life-saving technology companies focused on growing a safer, cleaner, healthier future for everyone, every day, today releases its scheduled trading update ahead of its financial year end on 31 March 2025.

 

Good progress in the second half; margin guidance modestly higher for full year

We have made good progress in the second half of this financial year to date, in varied trading conditions across our end markets amidst an evolving economic and geopolitical backdrop. This puts us on track for our 22nd consecutive year of record Adjusted profit1 and attests to the strength of our Sustainable Growth Model in delivering sustainable, compounding growth over the short and long term. This performance reflects the benefits we derive from the long-term growth drivers in our markets, the diversity of our portfolio, the exceptional talent within our companies and their agility to respond rapidly to changing market conditions.

 

The Group's organic revenue growth has been supported by order intake which remains ahead of both revenue in the year to date and the comparable period last year. Adjusted EBIT margin2 has benefitted from a better than expected performance across all three sectors, reflecting favourable product and portfolio mix and good operational delivery.

 

Based on this progress to date and current forecasts, we now expect an Adjusted EBIT margin2 modestly above 21% for the full year to March 2025, compared to prior guidance of around 21%. Our guidance for good organic constant currency3 revenue growth for the full year to March 2025 is unchanged from that given in our half year results announcement of 21 November 2024.

 

The appreciation of Sterling in the financial year is expected to have a negative currency translation effect on the Group's results5.

 

Healthy acquisition pipeline supported by a strong financial position

We completed seven acquisitions in the year to date across the Group's three sectors, with £158m invested (on a maximum total consideration basis6). We continue to have a healthy acquisition pipeline across all three sectors.

 

The strength of our cash generation supports these investments while enabling us to maintain a strong financial position with substantial capacity for future investment. Cash conversion for the full year is expected to be strong.

 

CFO succession

 

As previously announced, Carole Cran was appointed CFO Designate on 8 January 2025 and will succeed Steve Gunning as Group Chief Financial Officer on 1 April 20257.

 

Full Year Results

The Group's results for the year ending 31 March 2025 will be released on 12 June 2025.

 

For further information, please contact:

 

Halma plc

Marc Ronchetti, Group Chief Executive

+44 (0)1494 721 111

Steve Gunning, Chief Financial Officer

Charles King, Head of Investor Relations

+44 (0) 7776 685 948

Melanie Horton, Deputy Head of Investor Relations

+44 (0) 7554 013 396

MHP

Oliver Hughes / Rachel Farrington / Ollie Hoare

+44 (0)20 3128 8100 / +44 (0)7817 458 804

halma@mhpgroup.com

 

Notes:

1. Adjusted profit before tax is before amortisation and impairment of acquired intangible assets, acquisition items and profit or loss on disposal of businesses.

2. Adjusted EBIT is earnings before interest and tax, and before amortisation and impairment of acquired intangible assets, acquisition items, and profit or loss on disposal of businesses. Adjusted EBIT margin is defined as Adjusted EBIT expressed as a percentage of revenue.

3. Organic constant currency measures exclude the effect of movements in foreign exchange rates on the translation of revenue and profit into Sterling, as well as acquisitions in the year following completion and disposals.

4. The following guidance was given in our half year 2025 results announcement in November 2024: "For the year as a whole we expect to deliver good organic constant currency3 revenue growth, and an Adjusted EBIT margin2 of around 21%, in the middle of our target range."

5. Sterling has strengthened in the year relative to many currencies, including the US Dollar and Euro and the currency translation impact on the Group's results for the financial year ended 31 March 2025 is expected to be negative. Based on exchange rates of Sterling/US Dollar 1:1.29 and Sterling/Euro 1:1.19, we would expect approximately a £29m negative revenue effect and approximately a £8m negative profit effect in the 2025 financial year, compared to the 2024 financial year.

6. The seven acquisitions completed in the year to date are MK Test Systems Limited, G.F.E. - Global Fire Equipment, S.A., Advantronic Systems, S.L., RemLive Limited, Hathorn Corporation, Lamidey Noury Medical, SAS and Safe-Com Wireless LLC. Maximum total consideration is on a cash- and debt-free basis.

7. As announced on 8 January 2025, Steve Gunning informed the Board of his decision to retire from Halma. Steve will continue as CFO of Halma until 31 March 2025. In line with the Group's succession plans, Carole Cran, former independent non-executive director of Halma and Chair of the Audit Committee since 2016, was appointed CFO Designate on 8 January 2025 and will succeed Steve on 1 April 2025.

 

8. This Trading Update is based upon unaudited management accounts information. Forward-looking statements have been made by the Directors in good faith using information available up until the date that they approved this statement. Forward-looking statements should be regarded with caution because of the inherent uncertainties in economic trends and business risks.

9. A copy of this announcement, together with other information about Halma, may be viewed on our website www.halma.com.

About Halma

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day. Its purpose defines the three broad market areas where it operates:

· Safety - Protecting the safety of people and assets as increasing urbanisation puts pressure on crowded infrastructure.

· Environment - Addressing the impacts of climate change, pollution and waste, protecting life-critical resources and supporting scientific research.

· Health - Meeting the increasing demand for better healthcare as chronic illness rises, driven by growing and ageing populations and lifestyle changes.

Halma employs over 8,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

Halma has been named as one of Britain's Most Admired Companies for the past six years.

For more information www.halma.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSFUFUEEISELD
Date   Source Headline
28th May 20267:15 amRNSExecutive Board changes
13th Apr 20267:00 amRNSAcquisition
12th Mar 20267:00 amRNSTrading Update
13th Jan 20269:18 amRNSDirector/PDMR Shareholding
9th Jan 20261:26 pmRNSDirector/PDMR Shareholding
9th Jan 20267:00 amRNSAcquisition
5th Dec 20257:00 amRNSAcquisition
20th Nov 20257:00 amRNSHalf Year Results
1st Oct 20252:00 pmRNSDirector/PDMR Shareholding
26th Sep 202510:19 amRNSDirector/PDMR Shareholding
25th Sep 20257:00 amRNSTrading Update
26th Aug 20257:00 amRNSAcquisition
24th Jul 20252:15 pmRNSResult of AGM
30th Jun 202511:30 amRNSDirector/PDMR Shareholding
25th Jun 20258:30 amRNSAGM - Revised Form of Proxy
24th Jun 20259:20 amRNSDirector/PDMR Shareholding
20th Jun 20255:15 pmRNSAnnual Financial Report
18th Jun 20254:47 pmRNSDirector/PDMR Shareholding
12th Jun 20257:00 amRNSFull Year Results
16th May 20257:00 amRNSDirectorate Change
28th Mar 20251:10 pmRNSDirector/PDMR Shareholding
21st Mar 20252:00 pmRNSDirectorate Change
13th Mar 20257:00 amRNSTrading Update
28th Feb 20254:29 pmRNSDirector/PDMR Shareholding
14th Jan 20252:05 pmRNSDirector/PDMR Shareholding
8th Jan 20257:00 amRNSAppointment of Chief Financial Officer
28th Nov 202410:04 amRNSDirector/PDMR Shareholding
22nd Nov 20243:30 pmRNSDirector/PDMR Shareholding
22nd Nov 20243:26 pmRNSDirector/PDMR Shareholding
21st Nov 20247:00 amRNSHalf Year Results
18th Nov 20247:00 amRNSAcquisition
6th Nov 20242:34 pmRNSDirector Declaration
2nd Oct 20249:20 amRNSDirector/PDMR Shareholding
26th Sep 20247:00 amRNSTrading Update
24th Sep 20249:45 amRNSDirector/PDMR Shareholding
3rd Sep 20249:15 amRNSPDMR Shareholding
25th Jul 20241:51 pmRNSResult of AGM
24th Jul 20249:15 amRNSDirector/PDMR Shareholding
17th Jul 202412:46 pmRNSDirector Declaration
1st Jul 20249:51 amRNSDirector/PDMR Shareholding
27th Jun 20247:00 amRNSAcquisition
25th Jun 20243:00 pmRNSDirector/PDMR Shareholding
24th Jun 20245:26 pmRNSAnnual Financial Report
13th Jun 20247:00 amRNSFull Year Results
1st May 20247:00 amRNSAcquisition
19th Mar 20243:53 pmRNSDirector/PDMR Shareholding
14th Mar 20247:00 amRNSTrading Update
4th Mar 20247:00 amRNSAcquisition
21st Feb 20244:17 pmRNSDirector/PDMR Shareholding
30th Jan 20247:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.